Home
About
Overview
Sharing Data
ORCID
Help
History (45)
Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment.
Cardiovascular findings on chest computed tomography associated with COVID-19 adverse clinical outcomes.
Predictors of renal replacement therapy and mortality in children with chronic kidney disease.
Exciting inhibition in psychostimulant addiction.
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
See All 45 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
View in:
PubMed
subject areas
Anemia
Chronic Disease
Consumer Product Safety
Drug Labeling
Evidence-Based Medicine
Hematinics
Hemoglobins
Humans
Kidney Diseases
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Treatment Outcome
United States
United States Food and Drug Administration
Up-Regulation
authors with profiles
Ajaypal Singh